REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.
None
Unable to provide written informed consent to participate in this study
Known coronary artery disease at recruitment
History of previous coronary artery disease
Inability to acquire interpretable CT images
Cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago
Cohort
Prospective
Coronary CT
Diagnostic testScreening/Management Plan
Proportion of evaluated patients who should undergo CAD prevention
High clinical risk, or intermediate risk with CAC score \>0
Proportion with critical CAD
Coronary stenosis \>70% by CT coronary angiogram
Proportion at intermediate clinical risk
Intermediate clinical risk (0.8-2.0% annualized risk by Pooled Cohort Equation)
Statin responsiveness
Change in plaque volume
Click on the lead sponsor to view all of their trials.
Baker Heart and Diabetes Institute
Lead sponsor
Western Health, Australia
Collaborator
Northern Hospital, Australia
Collaborator
Menzies Institute for Medical Research
Collaborator
Peter MacCallum Cancer Centre, Australia
Collaborator
The Alfred
Collaborator
